Cytokinetics CYTK Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Cytokinetics (CYTK) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $257.94M in Q1 2026.
- How has Cytokinetics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- Cytokinetics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 6.5% year-over-year, from $275.73M to $257.94M.
- What is the long-term trend for Cytokinetics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 4 years (2021 to 2025), Cytokinetics's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 27.1% compound annual growth rate (CAGR), from $422.84M to $1.1B.